Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
255
resultados
Última actualización
26/06/2026 [06:53:00]
Resultados 125 a 150 de 255
Resumen de: WO2025034780A1
Provided are statistical copolymers derived from lipid carbonate monomers and cationic aminoester monomers useful in the delivery of nucleic acids across cell membranes, both in vitro and in vivo. The compounds described herein are shown to be particularly effective in delivery of mRNA into cells with resultant high protein expression, both in vitro and in vivo.
Resumen de: WO2025030426A1
Provided is a pharmaceutical preparation for treating Bietti's crystalline dystrophy (BCD), comprising a recombinant AAV expressing CYP4V2, sodium chloride, poloxamer, phosphate, and water for injection, and having a pH between 7.0 to 7.6. The pharmaceutical preparation has an excellent virus titer stability, very few AAV aggregates, a high mRNA expression of the target gene after multiple times of freezing and thawing, and/or an excellent high temperature stability. Moreover, the animal experiments in vivo demonstrate that the preparations with the formulations have an excellent property in reducing local inflammatory response of the retina, and further clinical trials demonstrate that the pharmaceutical preparations conform to the relevant technical specifications for safety and effectiveness in the Chinese Pharmacopoeia and the United States Pharmacopoeia (USP).
Resumen de: WO2025038450A1
Disclosed herein are compositions comprising engineered immune cells and immunomodulatory nanoparticles for localized targeted therapy in the treatment of cancer and other diseases, injuries, or conditions. The engineered immune cells comprise chimeric antigen receptors (CARs) that secrete bispecific immune cell engager (e.g., bispecific T cell Engagers ("BiTEs"), e.g., a bispecific macrophage engager, e.g., a bispecific neutrophil engager). The CAR.bispecific immune cell engager engineered immune cells are combined with silica nanoparticles (with or without the immune cell engager targeting ligands attached thereto) for combinatorial treatment of the disease or condition.
Resumen de: WO2024249559A2
Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.
Resumen de: EP4759299A1
The present application relates to zinc-magnesium layered hydroxide nanoparticles as a drug delivery system for the treatment of periodontitis and/or peri-implantitis. The nanoparticles herein described have a layered hydroxide structure, have enhanced cell interaction and uptake, are biodegradable, efficient at drug loading, have an improved, pH-responsive drug release profile, and enhanced biological efficacy. The application also discloses a method to obtain the zinc-magnesium layered hydroxide nanoparticles.
Resumen de: AU2024373408A1
The application relates to a lipid compound in Formula (I), a lipid nanoparticle containing it, a preparation method thereof, and a use in drug delivery.
Resumen de: WO2025080649A1
Disclosed herein are POEGMA-based block copolymers that have phase transition and self-assembly properties. The disclosed block copolymers can take advantage of these properties to form particles that can effectively encapsulate and deliver drugs. An example block copolymer includes a first block that includes POEGMA with ethylene glycol side chains of 2 monomers, 3 monomers, or combinations of both; and a second block that includes POEGMA with ethylene glycol side chains of 1 monomer, 2 monomers, or combinations of both. Also disclosed herein are compositions that include the block copolymers, methods of treating a disease or disorder, and methods of delivering a drug.
Resumen de: WO2025038371A1
A solid lipid nanoparticle (SLN) comprising an anionic form of a drug, which comprises a phosphate, a phenolate, or a carboxylate, entrapped in (a) a cationic form of the lipid SM-102 or a cationic form of the lipid ALC-0315, (b) distearoylphosphatidylcholine, (c) cholesterol, and (d) 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 or ALC-0159, wherein the anionic form of the drug and the cationic form of the lipid of (a) form an ionic complex or a salt; a SLN comprising an anionic form of a drug, which comprises a phosphate, a phenolate, or a carboxylate, entrapped in dimethyldidodecylammonium bromide or 1,2-dioleoyl-3-trimethylammonium-propane; pharmaceutical compositions comprising the SLNs; and methods of making the SLNs.
Resumen de: WO2025034764A1
Ionizable lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
Resumen de: WO2024249419A2
An antibacterial nanoparticle comprising an inner silica core; a gold (Au) nanosphere surrounding the inner silica core; a surface layer comprising silver (Ag) surrounding the gold nanosphere or the silver is alloyed into the gold nanosphere; and an antimicrobial peptide conjugated to the surface layer, wherein the antimicrobial peptide is selected from the group consisting of a cysteine terminated Syn71 peptide, a cysteine terminated MC1-2 peptide, and a cysteine terminated Syn20 peptide.
Resumen de: CN114340733A
The present invention provides a method for improving or accelerating wound healing in a subject, the method comprising administering to a wound in a subject in need thereof an agent that inhibits expression of a clock gene wherein the clock gene is neuronal PAS domain protein 2 (Npas2). The invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site and for reducing wound area size, comprising administering to a subject a bone loss site or a wound site, in particular an open wound site, an agent that inhibits the expression of Npas2.
Resumen de: WO2024243480A1
The application relates to ionizable lipids. The formulations of ionizable lipids can be used for the delivery of one or more nucleic acid therapeutic agents, for example mRNA, siRNA or miRNA. The compositions can include additional lipids, such as non-cationic lipids, PEG-modified lipids and optionally cholesterol.
Resumen de: CN122208553A
本发明属于生物医药技术领域，具体涉及靶向递送circAMY2B的试剂在制备抗食管癌药物中的应用。本发明的靶向递送circAMY2B的试剂在制备抗食管癌药物中的应用中，所述的试剂为靶向递送circAMY2B的脂质纳米颗粒。本发明具有如下技术效果：本发明首次将靶向递送 circAMY2B 的脂质纳米颗粒应用于抗食管癌药物的制备，开拓了circAMY2B 的临床应用新领域，为食管癌的治疗提供新的药物选择，具有以下显著优点：1、靶向性强，疗效显著；2、稳定性高，生物利用度好；3、生物安全性好，毒副作用低。
Resumen de: CN122208536A
本发明公开了一种胆酸修饰型姜黄素聚合物脂质纳米粒及其制备工艺，属于药物制剂技术领域。该纳米粒以姜黄素为模型药物，胆酸为修饰剂，聚己内酯为聚合物载体，大豆卵磷脂为脂质成分，泊洛沙姆188为表面活性剂，采用乳化溶剂挥发法制备而成。本发明通过单因素实验结合Box‑Behnken响应面设计优化制备工艺，确定最优处方参数，所制备的胆酸修饰型姜黄素聚合物脂质纳米粒（CUR@CA‑PLNs）包封率高、粒径分布均匀、稳定性良好，且具有pH响应释药特性，能显著改善姜黄素水溶性差、化学稳定性低等问题，同时保留姜黄素的抗氧化活性，为姜黄素的临床应用提供了一种高效、稳定的药物递送系统。
Resumen de: CN122213231A
本发明公开了一种基于抗人ICAM‑1单域抗体的靶向协同治疗体系及其应用。首先，本发明提供了一种新型抗人ICAM‑1单域抗体，该单域抗体对衰老细胞表面ICAM‑1有高亲和力和高选择性。其次，本发明利用该单域抗体对经过“低氧+自噬诱导”预处理的年轻化间充质干细胞进行表面工程化修饰，获得能特异性靶向衰老微环境的靶向性年轻化MSCs。最后，本发明将所述靶向性年轻化MSCs与包载SIRT1激活剂SRT1720的缓释纳米微球共同整合于温敏水凝胶中，形成一种组合物。该组合物能够高效、特异性地富集于衰老组织，并通过MSCs的旁分泌作用与药物的缓释释放产生协同效应，显著清除衰老细胞、逆转衰老相关分泌表型、改善线粒体功能并恢复组织活力，在抗衰老治疗领域具有广阔的应用前景。
Resumen de: CN122208591A
本发明公开了一种蔓荆子黄素纳米制剂的制备方法，属于中药制剂领域。该方法将丝素蛋白与泊洛沙姆F127溶于水中作为水相，将蔓荆子黄素溶于丙酮中作为有机相，在搅拌条件下将有机相逐渐滴加于水相中，挥除有机溶剂，即得纳米制剂。本发明制备工艺简便，所得纳米制剂粒径均一、分散性好，显著提高了蔓荆子黄素的水溶性和口服生物利用度，同时利用丝素蛋白的黏膜黏附性和泊洛沙姆的稳定作用，实现了肠道靶向蓄积，可用于溃疡性结肠炎等炎症性肠病的口服治疗。
Resumen de: CN122212960A
本发明提供一种可电离阳离子脂质化合物及其应用，所述可电离阳离子脂质化合物具有式I所示结构。所述可电离阳离子脂质化合物通过特定的结构设计，由其制备得到的脂质纳米颗粒（LNP）对核酸分子具有优异的负载能力和更高的递送效率，且可以显著提高核酸分子在体内的翻译表达水平。
Resumen de: CN122208755A
本发明公开了一种协同声动力‑免疫治疗的纳米系统及其制备方法和应用，所述制备方法包括采用Shewanella细菌膜包覆PEG修饰的BaTiO3纳米颗粒，得到B@BM；将高表达TIM‑3 scFv的工程化巨噬细胞膜与R848进行混合并进行超声处理，得到R@CM，再进行PAH修饰；将B@BM和PAH修饰的R@CM进行混合共挤出；该纳米系统能够高效产生ROS，以及诱导肿瘤细胞发生ICD，同时释放新抗原；并能够激活树突细胞/巨噬细胞，阻断TIM‑3/Galectin‑9通路，通过SDT、免疫检查点阻断以及TLR激活“三者协同”的策略，实现对结直肠癌的协调性清除，并建立长期免疫记忆。
Resumen de: CN122208785A
本发明涉及生物医药领域，具体涉及心肌损伤治疗药物及其制备方法和应用，心肌损伤治疗药物包括一种纳米粒，纳米粒包括具有中空介孔结构的普鲁士蓝，普鲁士蓝内封装有相变造影剂和β‑烟酰胺单核苷酸；普鲁士蓝的外侧包有脂质膜，脂质膜上修饰有缺血心肌靶向肽。通过本申请，构建了一种集特异性递送、时空控释与可视化诊疗于一体的多功能纳米载体系统，实现了精准治疗。
Resumen de: CN122208775A
本发明涉及功能性纳米药物技术领域，尤其是涉及一种羟基功能化聚酰胺‑胺树状大分子共负载纤连蛋白/依达拉奉的纳米药物及其制备与应用。该纳米药物为羟基功能化树状大分子与纤连蛋白通过物理间相互作用力形成纳米复合物，并负载依达拉奉得到的纳米药物；羟基功能化树状大分子为将第五代聚酰胺‑胺树状大分子与4‑(溴甲基)苯硼酸通过酰胺键连接，并通过缩水甘油羟基化修饰树状大分子表面得到的羟基功能化树状大分子。该纳米药物能够穿透血脑屏障，精准靶向病变部位，协同调控小胶质细胞、神经细胞和血管内皮细胞，通过调节脑卒中损伤区域氧化应激和免疫激活状态，创造利于神经保护和血管再生的脑免疫微环境，实现缺血性脑卒中的高效协同治疗。
Resumen de: WO2025146027A1
The present disclosure relates to a PEG lipid and the use thereof. The PEG lipid can be used for preparing a lipid nanoparticle that delivers an active ingredient. The present disclosure further relates to a pharmaceutical composition and a lipid nanoparticle comprising the PEG lipid, as well as the use thereof in preparing a pharmaceutical.
Resumen de: CN122208551A
本发明公开了一种肠上皮仿生纳米颗粒的构建方法及应用，属于纳米医学技术领域。所述肠上皮仿生纳米颗粒的制备方法为：将丁酸、丁酸盐或其衍生物负载于医用高分子材料的交联网络中；然后在其表面进一步包覆提取自肠上皮细胞的细胞膜，得到该纳米颗粒。其表面的膜受体能够吸附引起肠道屏障损伤的主要肠腔内诱发因素，同时负载的丁酸药物成分能够增强肠道屏障的功能。本发明肠上皮仿生纳米颗粒可以抑制典型消化系统肿瘤的发生、生长和转移。通过口服所述仿生纳米颗粒可通过减轻肠道屏障的破坏，有效抑制肝脏免疫微环境的紊乱，从而实现对肝细胞癌和结肠癌肝转移的强效抑制。强化肠道屏障为预防和治疗消化系统肿瘤指明了一种独特的策略。
Resumen de: CN122213245A
本发明公开了预防经典猪瘟的mRNA‑LNPs疫苗及其制备方法。本发明将猪瘟病毒E2蛋白分别与XCL1和泛素进行融合得到两种嵌合抗原，将编码两种嵌合抗原和单独E2的mRNA分别包封在脂质纳米颗粒中构建得到mRNA‑LNPs疫苗；在家兔和仔猪模型中系统评估了三种mRNA‑LNPs和E2亚单位疫苗的免疫原性及保护效果，结果显示，与未修饰的E2‑mRNA‑LNP和E2亚单位疫苗相比，经N端泛素修饰的Ub‑E2‑mRNA‑LNP和靶向树突状细胞的XCL1‑E2 mRNA‑LNP均可诱导强烈的体液和细胞免疫，且均可为感染猪瘟病毒强毒石门株的猪只提供完全保护，本发明提供的疫苗在预防经典猪瘟上具有应用前景。
Resumen de: CN122208549A
本发明提供一种视网膜光感受器细胞亲和肽‑LNP‑基因药物复合物及其应用，本发明通过在脂质纳米颗粒表面嵌合来源于层粘连蛋白或玻连蛋白等细胞外基质的亲和肽，实现了对光感受器细胞的高效靶向递送，显著提高基因药物在视网膜光感受器细胞中的递送效率和表达效率，并在视网膜退行性病变模型中表现出明确的视功能修复效果。该技术具有递送效率高、生物相容性好、靶向性强及可扩展性强等优点，为视网膜退行性疾病及相关眼科疾病的基因药物治疗提供了一种新的技术路径。
Nº publicación: CN122213253A 16/06/2026
Solicitante:
西安交通大学
Resumen de: CN122213253A
本发明公开了具有软骨靶向特性的重组腺相关病毒、其包装系统、制备方法及应用，属于生物医药与基因治疗技术领域。本发明通过在rAAV衣壳的表面特定位点插入软骨组织靶向肽，使rAAV具备针对软骨的主动靶向能力。与常规rAAV 2/9相比，利用本发明制备的软骨靶向rAAV，可显著提高外源基因在软骨中的转导效率和表达水平，同时有效降低rAAV在肝脏等非靶向内脏组织中的富集程度及潜在毒副作用，为治疗骨关节炎等软骨相关疾病的基因治疗，提供了更安全、高效的AAV递送工具。
BOPI
Sede Electrónica
